A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Hypertension is a global health concern requiring effective pharmacologic management.
• Azilsartan is an angiotensin II receptor blocker used for hypertension treatment.
• No comprehensive meta-analysis of azilsartan's efficacy in blood pressure reduction has been published.

Purpose of the Study:

• To conduct the first meta-analysis of randomized controlled trials (RCTs) evaluating azilsartan for blood pressure reduction in hypertensive patients.
• To quantify the efficacy of azilsartan compared to control therapies in lowering systolic and diastolic blood pressure.

Main Methods:

• A systematic literature search was performed on MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials up to March 2013.
• Eligible studies included prospective RCTs of azilsartan (or azilsartan medoxomil) versus any control, reporting clinic or 24-hour mean blood pressure outcomes.
• Data from 7 RCTs involving 6152 patients were pooled to calculate mean differences and 95% confidence intervals for blood pressure changes.

Main Results:

• Pooled analysis revealed a statistically significant reduction in blood pressure with 40 mg azilsartan compared to control therapy.
• Reductions observed included clinic systolic BP (-4.20 mmHg), clinic diastolic BP (-2.58 mmHg), 24-h mean SBP (-3.33 mmHg), and 24-h mean DBP (-2.12 mmHg).
• All observed reductions were statistically significant (P < 0.00001).

Conclusions:

• Azilsartan therapy demonstrates superior efficacy in reducing blood pressure among patients with hypertension compared to control therapies.
• This meta-analysis provides robust evidence supporting azilsartan's role in managing hypertension.
• Further research may explore long-term outcomes and comparative effectiveness against other antihypertensive agents.